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More on STAT1 Gain of Function, Type 1 Diabetes,  
and JAK Inhibition
To the Editor: Chaimowitz et al. (Oct. 8 issue)1 
report diabetes remission following ruxolitinib 
treatment in a patient with a signal transducer 
and activator of transcription 1 (STAT1) gain-of-
function mutation.1 This work is exciting and 
important, but we believe the authors were incor-
rect in referring to the diabetes in this mono-
genic autoimmune syndrome as type 1 diabetes.
Although both type 1 diabetes and diabetes 
in monogenic autoimmune syndromes are auto-
immune diseases, with the associated islet auto-
antibodies, there is a crucial difference in their 
genetic susceptibility and hence their cause. 
Type 1 diabetes is a polygenic autoimmune dis-
ease with well-described associations with com-
mon variants in the HLA locus.2 In contrast, the 
diabetes described by Chaimowitz et al. is 
caused by a highly penetrant variant in a single 
gene in a monogenic autoimmune form of dia-
betes and is not associated with HLA.3,4 Specific 
immunomodulatory therapy can be chosen on 
the basis of the specific gene or pathway in-
volved in monogenic autoimmunity, as shown by 
the authors, but the difference in causation 
means it is unlikely that the same therapy will 
prevent the development of the far more com-
mon type 1 diabetes.5 We believe that diabetes in 
any monogenic autoimmune condition should 
be referred to as monogenic autoimmune diabe-
tes and should include its gene name — in this 
case, STAT1-monogenic autoimmune diabetes 
— rather than being referred to by the term 
“type 1 diabetes.”
Matthew B. Johnson, Ph.D. 
Andrew T. Hattersley, D.M., F.R.C.P. 
Kashayp A. Patel, Ph.D., M.R.C.P.
University of Exeter 
Exeter, United Kingdom 
k . a . patel@ exeter . ac . uk
No potential conflict of interest relevant to this letter was 
reported.
1. Chaimowitz NS, Ebenezer SJ, Hanson IC, Anderson M, 
Forbes LR. STAT1 gain of function, type 1 diabetes, and reversal 
with JAK inhibition. N Engl J Med 2020; 383: 1494-6.
2. Erlich H, Valdes AM, Noble J, et al. HLA DR-DQ haplotypes 
and genotypes and type 1 diabetes risk: analysis of the Type 1 
Diabetes Genetics Consortium families. Diabetes 2008; 57: 1084-
92.
3. Johnson MB, Patel KA, De Franco E, et al. A type 1 diabetes 
genetic risk score can discriminate monogenic autoimmunity 
with diabetes from early-onset clustering of polygenic autoim-
munity with diabetes. Diabetologia 2018; 61: 862-9.
4. Johnson MB, Hattersley AT, Flanagan SE. Monogenic auto-
immune diseases of the endocrine system. Lancet Diabetes En-
docrinol 2016; 4: 862-72.
5. Warshauer JT, Bluestone JA, Anderson MS. New frontiers in 
the treatment of type 1 diabetes. Cell Metab 2020; 31: 46-61.
DOI: 10.1056/NEJMc2032806
The authors reply: Our use of the term “type 1 
diabetes” in this report aligns with published 
guidelines that define type 1 diabetes as insulin 
deficiency with loss of proper beta-cell function 
and the presence of islet autoantibodies.1 Cur-
rently, the definition of type 1 diabetes is broad 
and includes both autoimmune and idiopathic 
diabetes. An increasing number of rare genetic 
mutations, such as the STAT1 gain-of-function 
mutation, are strongly associated with autoim-
mune diabetes.2 However, we would note that the 
association is incomplete and probably involves 
genetic interactions with other risk variants pres-
ent in polygenic autoimmune diabetes that in-
clude the HLA locus.3 Thus, autoimmune islet 
destruction in both polygenic and monogenic 
forms of diabetes may not be distinct but rather 
share commonalities, including a similar reper-
toire of autoreactive T cells and B cells. Accord-
ingly, we believe that this particular report of 
diabetes reversal may be instructive beyond the 
rare constellation of findings in our patient. 
Nonetheless, we agree that a more refined defi-
nition of type 1 diabetes is important given the 
overall umbrella of autoimmune diabetes, which 
could be further subdivided into polygenic and 
monogenic subtypes.
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